Skip to main content

Table 3 Meta-analysis evaluating the adjusted association between HBV infection and NHL subtypes and by region

From: Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma

Type

overall OR

High prevalence countries OR (95% CI)

Intermediate prevalence countries OR (95% CI)

Low prevalence countries OR (95% CI)

NHL

2.09 (1.76–2.50)

(*P < 0.01) n = 35

2.20 (1.78–2.72)

(P < 0.01) n = 15

2.48 (1.55–3.95)

(P < 0.01) n = 10

1.64 (1.15–2.34)

(P < 0.01) n = 10

DLBCL

2.15 (1.52–3.02)

(P < 0.01) n = 14

2.69 (1.88–3.86)

(P < 0.01) n = 6

3.38 (2.13–5.36)

(P = 0.47) n = 3

1.14 (0.58–2.26)

(P < 0.01) n = 5

BL

2.22 (0.87–5.66) (P < 0.01) n = 7

1.50 (0.94–2.40)

(P = 0.79) n = 6

n = 0

n = 1

CLL/SLL

1.37 (0.93–2.00) (P < 0.01) n = 11

1.61 (1.00–2.58)

(P = 0.09) n = 5

n = 1

1.33 (0.66–2.67)

(P = 0.02) n = 5

FL

1.81 (1.12–2.94) (P < 0.01) n = 13

2.42 (1.36–4.32)

(P < 0.01) n = 6

4.17 (2.06–8.46)

(P = 0.71) n = 2

0.85 (0.44–1.66)

(P = 0.02) n = 5

NK/T

1.30 (0.82–2.08)

(P = 0.06) n = 7

1.23 (0.76–1.89)

(P = 0.04) n = 5

4.51(0.56–36.25)

(P = 0.57) n = 2

n = 0

PTCL

1.31 (0.89–1.91) (P = 0.44) n = 4

1.31 (0.89–1.91)

(P = 0.44) n = 4

n = 0

n = 0

ALCL

3.23 (1.27–8.18) (P = 0.04) n = 3

3.23 (1.27–8.18)

(P = 0.04) n = 3

n = 0

n = 0

  1. Abbreviations: NHL = non-Hodgkin lymphoma, HBV = hepatitis B virus, OR = odds ratio, CI = confidence interval, DLBCL = diffuse large B-cell lymphoma, BL = Burkitt’s lymphoma, FL = follicular lymphoma, CLL/SLL = small lymphocytic lymphoma/chronic lymphocytic leukemia, NK/T = NK/T cell lymphoma, PTCL = peripheral T-cell lymphoma, ALCL = anaplastic large cell lymphoma. * Statistically significant at the 0.05 alpha level